Echo Therapeutics Announces Closing of Approximately $2.3 Million Private...(inancing have not been registered undert...),Health

Date:2/12/2008

inancing have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an exemption from the registration requirements under the Securities Act. This notice does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled specialty pharmaceuticals and diabetes management company. Echo's Symphony(TM) CTGM System is a new needle- free, wireless, continuous transdermal glucose monitoring system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo's patented AzoneTS(TM) transdermal drug delivery technology is focused on building a pipeline of proprietary reformulations of specialty pharmaceutical products previously approved by the U.S. Food and Drug Administration (FDA). Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve(TM), Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding Echo's offering of convertible senior notes. Factors that could adversely affect Echo's business and prospects are described in Echo's filings with the Securities and Exchange Commissio
'/>"/>

SOURCE Echo Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
2. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
3. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
4. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
5. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
6. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
7. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
8. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
11. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis